Article

Early insights into viability of Ebola monoclonal antibodies for the 2026 Bundibugyo virus disease outbreak

2026-07-15

Abstract excerpt

<title>Abstract</title> <p>The 2026 Bundibugyo virus disease (BVD) outbreak in the DRC and Uganda raises urgent questions about the efficacy of existing Ebola virus (EBOV) monoclonal antibodies (mAbs) against Bundibugyo virus (BDBV). Here, we perform genomic and structural analyses of 44 BDBV sequences, including 12 from the 2026 outbreak, to assess mAb binding to the viral glycoprotein (GP). While the MBP134 coc...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 46ad2db5-5f95-542c-93b8-8b768bfc9c7e
DOI: 10.21203/rs.3.rs-10270397/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Early insights into viability of Ebola monoclonal antibodies for the 2026 Bundibugyo virus disease outbreakDOI 10.21203/rs.3.rs-10270397/v1Read

Mutation mapping and evolutionary dynamics of Bundibugyo Ebolavirus (BDBV-2026) genomes reported from UgandaSemantic proximity Read

Monoclonal antibodies for the treatment of Ebola virus disease.Semantic proximity Read

Expanding the watch list for potential Ebola virus antibody escape mutationsSemantic proximity Read

Comparative Time–Space Evolution of Bundibugyo Ebolavirus Glycoprotein Across the 2007, 2012, and 2026 OutbreaksSemantic proximity Read

Cross-reactive neutralizing human survivor monoclonal antibody BDBV223 targets the ebolavirus stalkSemantic proximity Read

A broadly-neutralizing antibody against <i>Ebolavirus</i> glycoprotein that potentiates the breadth and neutralization potency of other antibodiesSemantic proximity Read

Human antibody cocktail deploys multiple functions to confer pan-ebolavirus protectionSemantic proximity Read

DNA-delivered antibody cocktail exhibits improved pharmacokinetics and confers prophylactic protection against SARS-CoV-2Semantic proximity Read

Reversion of Ebolavirus Disease from a Single Intramuscular Injection of a pan-Ebolavirus ImmunotherapeuticSemantic proximity Read

Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus.Semantic proximity Read

Escape of SARS-CoV-2 variants KP1.1, LB.1 and KP3.3 from approved monoclonal antibodiesSemantic proximity Read

Structural Basis of Pan-Ebolavirus Neutralization by a Human Antibody against a Conserved, yet Cryptic EpitopeSemantic proximity Read